Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 247

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 247
---
 value 
              C$ |
| Outstanding at December 31, 2024 |     | 1,185,000 |     |           2.06 |     |             4.18 |     |            1.89 |
| Outstanding at March 31, 2025    |     | 1,185,000 |     |           2.06 |     |             3.94 |     |            1.66 |
| Exercisable at March 31, 2025    |     |   927,500 |     |           1.46 |     |             3.59 |     |            2.26 |
| Unvested at March 31, 2025       |     |   257,500 |     |           3.68 |     |             4.69 |     |            0.04 |

As of March 31, 2025 there were $455,175 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of 2.00. For the three months ended March 31, 2025 and 2024, stock-based compensation expense was $112,277 and $35,953, respectively. Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations and comprehensive loss within the line items 'general and administrative' and 'research and development' expenses.

7. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

|                                                                      |   | Three months ended March 31, 
                         2025 |   |   |       2024 |   |
|:---------------------------------------------------------------------|:--|-----------------------------:|:--|:--|-----------:|:--|
| Net loss attributable to shareholders                                | $ |                   (5,102,408 | ) | $ | (1,707,358 | ) |
| Weighted average number of common shares outstanding during the year |   |                   12,240,437 |   |   |  8,076,673 |   |
| Basic and diluted net loss per share attributable to shareholders    | $ |                        (0.42 | ) | $ |      (0.21 | ) |

The Company's potentially dilutive securities for the three months ended March 31, 2025 and 2024, include stock options, warrants, and notes payable. The